Premium
Phase 3 study finds once‐daily valbenazine improves symptoms of tardive dyskinesia
Publication year - 2017
Publication title -
the brown university psychopharmacology update
Language(s) - English
Resource type - Journals
eISSN - 1556-7532
pISSN - 1068-5308
DOI - 10.1002/pu.30240
Subject(s) - tardive dyskinesia , medicine , dosing , placebo , pharmacology , psychiatry , vesicular monoamine transporter 2 , dyskinesia , monoamine neurotransmitter , schizophrenia (object oriented programming) , alternative medicine , pathology , receptor , disease , parkinson's disease , serotonin
Once‐daily dosing of the vesicular monoamine transporter 2 (VMAT2) inhibitor valbenazine resulted in significant improvement over placebo in patients with tardive dyskinesia (TD) and an underlying psychotic or mood disorder, a Phase 3 trial has found. Soon after the study's publication online March 21 in the American Journal of Psychiatry , the Food and Drug Administration approved valbenazine as the first available treatment for TD (see From the FDA, page 8).